Navigation Links
Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
Date:10/6/2007

- Results of animal studies distinguish liver effects of apoB inhibition

from MTP inhibition and support liver safety of ISIS 301012 - Favorable changes in liver fat metabolism associated with apoB inhibition

but not MTP inhibition - Results presented in an oral session today at DALM Symposium in New York

City - Isis will host a conference call on Monday, October 8, at 8:00 a.m. E.T.

at http://www.isispharm.com

CARLSBAD, Calif., Oct. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced new results of preclinical studies reaffirming the safety profile of ISIS 301012 and enhancing the understanding of its activity in the liver presented by Richard Lee, Ph.D. of Isis in a 3:45 p.m. oral session today at the Drugs Affecting Lipid Metabolism (DALM) XVI International Symposium in New York City. Isis will host a conference call Monday morning at 8:00 a.m. E.T. to discuss these results along with results of Phase 2 studies of ISIS 301012 presented at DALM.

The preclinical data presented provide a mechanistic explanation for Isis' previous observations that, in mice and monkeys, treatment with antisense inhibitors of apolipoprotein B-100 (apoB) is associated with reduced liver fat content. This observation is in contrast to the effects of either small molecule or antisense inhibitors of microsomal triglyceride transfer protein (MTP), another component of the cholesterol export pathway, which cause severe liver fat accumulation in the same animal models.

In the study reported today at DALM, Isis demonstrated that apoB inhibition led to compensatory changes in liver fat metabolism including reduced fat production and increased fat breakdown. These changes were documented in metabolic indicators measured in the blood serum and were accompanied by consistent changes in liver gene expression profiles. Having now developed the appropriate tests and demonstrated that serum metabolites are relevant indicators of liver fat metabolism in preclinical studies, Isis plans to incorporate similar measurements in its future clinical trials of ISIS 301012.

ABOUT ISIS 301012 AND CHOLESTEROL

ISIS 301012 is a second-generation antisense drug that reduces the production of apoB-100, a protein critical to the synthesis and transport of "bad" cholesterol and a target that has proved to be undruggable using traditional, small-molecule approaches. Cholesterol can be carried in the bloodstream in a variety of forms, with high-density lipoprotein, or HDL-C, being the good form, and low-density lipoproteins, or LDL-C, and very low-density lipoproteins, or VLDL-C, being bad forms directly involved in heart disease. Collectively, LDL-C, VLDL-C, and other bad forms of cholesterol are referred to as "non-HDL-C." The lowering of non-HDL-C is a key component in the prevention and management of cardiovascular disease. Isis plans to develop ISIS 301012 as the drug of choice for patients who are unable to achieve target cholesterol levels with statins alone or who are intolerant of statins. Isis has selected 200 mg/week as its development dose for future studies, including the registration studies for FH and the long-term coadministration study planned for patients with routine high cholesterol, both expected to begin this year.

Conference Call Information

At 8:00 a.m. Eastern Time Monday, October 8, Isis will conduct a live webcast conference call to discuss ISIS 301012 results. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 888-211-7384 (U.S.) / 913-312-0380 (International). A replay will be available for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS 301012 in treating patients with high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward- looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, and its quarterly report on Form 10-Q for the quarter ended June 30, 2007, which are on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals, Ibis Biosciences and Ibis T5000 are registered trademarks or trademarks of Isis Pharmaceuticals, Inc.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec 8, 2016 Research and Markets has announced ... report to their offering. ... This report analyzes the worldwide markets for Endodontic Supplies ... Canada , Japan , Europe ... Rest of World. Annual estimates and forecasts are provided for the ...
(Date:12/8/2016)... Dec. 8, 2016   TriNetX , the ... Children,s Hospital signed a membership agreement to ... development of new cures. The TriNetX ... 57 million patients globally, biopharmaceutical companies and contract ... improve protocol design, site selection, patient recruitment, and ...
(Date:12/8/2016)... 8, 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... today announced positive results from a Phase 3, ... the safety and efficacy of IDP-118 (halobetasol propionate ... psoriasis. Within the Phase 3 ... severe psoriasis, IDP-118 showed statistical significance to vehicle ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... , ... "I had a terrible time trying to get my grandson to ... the nebulizer had a more child-friendly design, then children would be more likely to ... NEBY to avoid the need to deliver medication via a nebulizer mask. The design ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... distinction by the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in ... and patient safety. Only a few hospitals and facilities have earned this distinction. ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for Input to ... Medical Informatics . , Results of the comparative usability study demonstrate that a ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... ... ... Premier Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the ... their world headquarters of Omni La Costa Resort & Spa in San Diego. , ... loss, personal development, a healthy lifestyle, or mental and physical healing. The week-long wellness ...
Breaking Medicine News(10 mins):